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Abstract 
Organisms living under aerobic conditions need oxygen for the metabolic conversion of 
nutrition into energy. With the appearance of increasingly complex animals, a specialized 
transport system (erythrocytes) arose during evolution in order to provide oxygen to virtually 
every single cell in the body. Moreover, in case of low environmental pO2 the number of 
erythrocytes automatically increases to preserve sustained oxygen delivery. This process 
relies predominantly on the cytokine erythropoietin (EPO) and its transcription factor hypoxia 
inducible factor (HIF), whereas the von Hippel Lindau (VHL) ubiquitin ligase as well as the 
oxygen-sensitive prolyl hydroxylases (PHDs) represent essential regulators of this oxygen-
sensing system. Deregulation of particular members of this pathway (e.g. PHD2, HIF2α and 
VHL) lead to disorders in blood homeostasis due to insufficient (anemia) or excessive 
(erythrocytosis) red blood cell production.  
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Introduction 
High altitude is accompanied by low atmospheric oxygen pressure, which sequentially leads 
to insufficient oxygen uptake and reduced tissue oxygenation. In general, inadequate oxygen 
supply is detrimental and might lead to death of cells, tissues or ultimately even the organism. 
In order to avoid this complex cardiovascular, respiratory and hematological mechanisms 
have evolved, and one such long-term adaptation process is the elevation of erythrocyte 
numbers to boost the blood’s oxygen transport capacity.  
As early as in the 19th century, scientists recognized the correlation between low atmospheric 
oxygen pressure and elevated red blood cell numbers in humans and animals.1 Some decades 
later, it became evident that low oxygen does not directly act on hematopoietic cells but 
induces the production of a soluble factor called erythropoietin (EPO). In 1977, EPO was 
purified from the  urine of anemic patients2 and in 1985 the corresponding EPO gene was 
isolated and cloned.3 About two decades ago, the transcription factor HIF (hypoxia inducible 
factor) was first identified in hepatoma cells as the regulator of EPO through its binding to a 
hypoxia responsive element (HRE) present in the 3’enhancer region of the EPO gene.4,5 In 
subsequent work, HIF was found to be expressed widespread in mammalian cells and even in 
lower animals that do not produce Epo or red blood cells.6-8 In the past decennium a lot of 
knowledge has been acquired on the role of HIFs during red blood cell production 
(erythropoiesis). Accordingly, this review aims to discuss recent findings on these essential 
proteins in humans and mice, and the detrimental impact of their deregulation.  
 
 
 
Erythropoietin: the driving force of erythropoiesis 
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EPO, a glycoprotein hormone, is the principal stimulator of erythropoiesis and is induced 
under hypoxic conditions. In 1957, the kidney was first identified as the primary EPO 
producing organ in adult mammals,9 whereas the liver is the major source of EPO during 
embryogenesis (e.g. hepatocytes, Ito cells). In the kidney, a specialized EPO-producing cell 
(REPC) was identified in the cortex and outer medulla that was initially described as an 
interstitial fibroblast-like cell with neuronal characteristics.10-14 Interestingly and in contrast to 
other organs, the kidney is able to increase the total amount of REPCs in an oxygen-
dependent manner rather than increasing EPO expression per cell.11,14 Neurons and glial cells 
in the central nervous system (CNS) represent an additional source of EPO15,16, it has been 
suggested that the glycohormone functions in a paracrine fashion as a protective,17 
ventilations18 or cognition-enhancing factor.19  
Erythropoiesis is a complex multistep process during which erythroid progenitors enucleate 
and develop into mature red blood cells. Upon Epo binding to its receptor, the EpoR signaling 
through the Janus kinase 2 (JAK2) activates multiple pathways including Stat5, 
phosphoinositide-3 kinase (PI-3K)/Akt, and p42/44 mitogen-activated protein kinase 
(MAPK). This reduces apoptosis and promotes expansion and differentiation of the 
progenitors.20 In adult mammals, erythropoiesis is mainly carried out by the bone marrow. 
However, in response to stress (e.g. anemia / bone marrow transfer / certain diseases), 
erythropoiesis may extend to extramedullary sites, such as spleen and liver, thereby increasing 
erythrocyte output. As shown in mice, stress erythropoiesis is characterized by massive self-
renewal of BFU-E (burst-forming unit-erythroid) cells and is regulated by additional extrinsic 
factors like the stress hormone cortisol, stem cell factor (SCF) and the bone morphogenetic 
protein 4 (BMP4).21-24 In humans, analogous pathways have not yet been identified, and the 
molecular basis is also not well described. However, recently, erythroblastic island 
macrophages have been reported to facilitate human stress and pathological erythropoiesis.25 
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The HIF pathway  
The HIF pathway is present in virtually every cell of the body, orchestrating a whole cascade 
of downstream genes that allow acclimatization to reduced levels of oxygen. The alpha 
subunit of the HIFs (mainly HIF1α and HIF2α) becomes stabilized nearly instantaneously 
during low oxygen conditions26 and translocates to the nucleus where it dimerises with the 
constitutively expressed HIFβ subunit and promotes transcription of genes containing a 
HRE.27 In human cells, pan-genomic analyses of HIF binding to DNA have now revealed the 
existence of more than 500 direct transcriptional targets of HIF in a given cell line.28,29 More 
than a decade ago, the groups of Dr. Ratcliffe and Dr. Kaelin discovered that both HIF1α and 
HIF2α are regulated at the post-transcriptional level by the HIF prolyl-hydroxylase domain 
enzymes (PHDs). These oxygen sensors hydroxylate the alpha-subunits and prime them for 
poly-ubiquitination by the von Hippel-Lindau (VHL) tumor suppressor complex which 
ultimately leads to proteolytic degradation (Figure 1).30,31 To date, four PHDs have been 
identified in mammals, of which PHD2 (gene name: Egl nine homolog 1 (Egln1)) has been 
described as the key limiting enzyme targeting HIFα for degradation under normoxic and 
mild hypoxic conditions.32-34  
HIF1α exhibits a ubiquitous expression pattern whereas HIF2α is found in a limited number 
of cell types including endothelial cells, cardiomyocytes, hepatocytes, glial cells and 
interstitial cells of the kidney.35 Both isoforms have overlapping sets of target genes, but can 
also play non-redundant roles, depending on the cell type and oxygen concentrations.36 
Accordingly, HIF1α has been suggested to represent the response to acute hypoxia, while 
HIF2α is the predominant subunit to chronic exposure to low oxygen as occurring at high 
altitude.37 In addition, several studies have demonstrated that both HIF isoforms can even 
display opposing roles in vivo, for instance in renal cell carcinoma growth and metastasis 
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formation.38,39 Glycolysis enzymes like phosphoglycerate kinase 1 (PGK1) and lactate 
dehydrogenase A (LDHA) are predominantly HIF1α-dependent.36 In contrast, HIF2α has 
been described to induce matrix metallopeptidase 9 (MMP9) and the transcription factor oct-
4, that is involved in stem cell function and in the elevation of hemoglobin gene expression in 
humans (Figure 1).40-42 Until recently, it was unclear which of the HIF and PHD isoforms 
regulated erythropoiesis and the expression of EPO in particular. Only with knowledge gained 
from patients with erythrocytosis and transgenic mice it became evident that the HIF2α 
isoform and not HIF1α is the key player in EPO gene expression and erythropoiesis-
enhancing processes (e.g. iron absorption and transport). 
 
Mutations in HIF pathway proteins can lead to erythrocytosis in humans 
Erythrocytosis is an aberrant increase in red blood cell number and comprises a heterogeneous 
group of disorders. A general distinction is made between the hypersensitivity of the erythroid 
progenitors to EPO (primary erythrocytosis) and the excessive activation of EPO gene 
transcription (secondary erythrocytosis). The most common example of primary 
erythrocytosis is Polycythemia Vera (PV). Here, erythroid progenitors carry a gain-of-
function mutation in the JAK2 gene, which leads to constitutive activation of the EPO 
signaling pathway at the EPO-R level. On the other hand, patients bearing point mutations in 
specific members of the HIF pathway can develop secondary erythrocytosis (Table 1). 
VHL 
In 1997, the first type of erythrocytosis related to the HIF pathway was discovered by Dr. 
Prchal and colleagues. They described 103 individuals suffering from erythrocytosis that 
belong to 81 families living in the Chuvash region (Russia).43 A number of patients were 
studied in detail and displayed markedly increased hematocrit levels accompanied by 
significantly higher EPO levels. However, molecular analysis failed to demonstrate mutations 
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in the EPO-R or previously described erythrocyte alterations (e.g. high oxygen affinity 
hemoglobin). Subsequent genetic studies revealed a homozygous mutation in the VHL gene 
(C598T leading to the R200W amino acid change) in all affected individuals. This resulted in 
reduced affinity of VHL for the hydroxylated HIFα subunit and subsequent increase of EPO 
and red blood cells.44,45 Recently, the underlying molecular mechanism was discovered: the 
R200W VHL mutation alters the affinity of VHL for suppression of cytokine signaling 1 
(SOCS1), which prevents the degradation of the EPO-R coupled kinase pJAK2.46 This 
illustrates that VHL, as part of the oxygen sensing machinery, does not only influence the 
production of EPO but also regulates erythropoiesis at different levels. The clinical 
presentation of Chuvash erythrocytosis patients has been carefully studied and includes a 
wide range of hematological and vascular abnormalities but no tumors. Chuvash patients 
suffer from complications such as thrombosis, major bleeding episodes and higher systolic 
pulmonary artery pressure, which collectively lead to premature lethality.47-49 However, it has 
been suggested that thromboembolic events in patients with VHL mutations might be 
associated with a subsequent gain in HIFα activity rather than the increase in red blood cell 
mass. For instance, VEGF and PAI-1, two HIFα targets, are upregulated in the serum of 
Chuvash erythrocytosis patients, and might have an impact on coagulation pathways.50,51 
Further studies have revealed higher homocysteine levels in Chuvash erythrocytosis patients, 
which could be an additional cause for the observed elevated blood pressure and thrombosis.52 
Later, another cohort with the same mutation was identified on an island in the Bay of Naples, 
Italy, which suggested for a founder mutation. Indeed, single nucleotide polymorphism 
(SNP)-analysis near the VHL gene on individuals from different ethnic backgrounds 
confirmed this, indicating that the R200W mutation arose between 14,000 and 62,000 years 
ago in a single ancestor.53,54 Apart from the R200W mutation, two additional homozygous 
VHL mutations (Croatian H191D and P138L) and several (compound) heterozygous 
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mutations have been discovered in single patients, resulting in very similar phenotypes 
observed in classical Chuvash patients.55-59 Conversely, the well-known autosomal dominant 
cancer-predisposition von Hippel-Lindau (VHL) syndrome, with over 1500 known VHL 
mutations, does not lead to erythrocytosis and is due to inheritance of a single mutated allele 
of VHL.60 
 
PHD2 
Since 2006, several patients and families with heterozygous loss-of-function mutations in the 
PHD2 gene have been described.55,61-64 The first mutations that were discovered are the 
P317R and the P371H variants, that affect the catalytic rate and substrate binding of PHD2, 
leading to partial inhibition of HIF hydroxylation.64-66 A few of the reported PHD2 mutations, 
apart from erythrocytosis, also led to other pathologies such as superficial thrombophlebitis64, 
sagittal sinus thrombosis66 and hypertension67. However, the number of such patients is 
currently still too small to draw firm conclusions. Only in one case, PHD2 has also been 
described to be associated with tumor formation - in particular, a recurrent paraganglioma. 
This patient is a heterozygous carrier of a PHD2 germline mutation (H374R) which affects 
one of the three conserved amino acids that coordinate Fe2+ binding, therefore contributing to 
the functionality of the enzyme.68 Interestingly, sequence analysis of the removed tumor mass 
showed that not one but both PHD2 alleles were mutated in the tumor cells (loss of 
heterozygosity). Functional analysis of the described PHD2 variants revealed that only the 
H374R variant has a detrimental effect, and all other studied PHD2 mutations show only 
weak deficiency in HIFα regulation.63 Such functional differences may permit PHD2 to act as 
a tumor suppressor in patients. 
 
HIF2α 
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A new form of familial erythrocytosis was discovered in a family where the phenotype was 
associated with a heterozygous missense mutation in the HIF2α gene (EPAS1). The mutation 
is predicted to produce a G537W change in the amino acid sequence of HIF2α, which is very 
close to the primary site of hydroxylation (Pro-531).69 The resulting impairment of the 
hydroxylation of HIF2α and its subsequent VHL binding leads to an aberrant stabilization of 
this transcription factor during normoxia. Further studies have revealed numerous other 
HIF2α alterations, all near the primary hydroxylation site, typically leading to elevated EPO 
levels and erythrocytosis in the affected patients.55,70 In addition, numerous SNPs in the 
HIF2α gene are found in Tibetans and are associated with only a moderate increase in 
hemoglobin concentrations. This adaptation to high altitude strengthens the link between 
HIF2α and erythropoiesis.71,72  Contrarily, mutations of the HIF1α isoform have not been 
associated with altered red blood cell production.  
Interestingly, mutations of the HIF2α gene have not only been shown to lead to erythrocytosis 
but have also been recently described to cause neoplasia. In particular, one patient carrying an 
inherited gain-of-function mutation in HIF2α (F374Y) displayed erythrocytosis, with 
additional recurrent multiple paragangliomas.73 In addition, two erythrocytosis patients with 
paragangliomas, one of them with an additional somatostatinoma, have also been described to 
carry somatic HIF2α mutations (A530T and A530V), which increase the half-life of the 
HIF2α subunit and enhance HIF downstream signaling.74 The mutation was found in DNA 
from the tumor cells only and not in other cell types nor in the patients’ parents, which argues 
for a causative postzygotic event.74 Screening of patients with chromaffin-cell tumors 
(paragangliomas, pheochromocytomas) led to the discovery of numerous other somatic HIF2α 
mutations which are only partially accompanied by erythrocytosis.75-78 This predicts a direct 
oncogenic role for HIF2α, independent of its impact on red blood cell production. 
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Taken together, patients bearing a polymorphism in VHL, PHD2 or HIF2α collectively 
highlight the importance of the HIF signaling pathway in red blood cell homeostasis. Both 
somatic and germline mutations in HIF pathway members have been shown to lead to 
erythrocytosis. In some cases, erythrocytosis was accompanied by neuroendocrine tumors 
whose molecular basis remains to be unraveled (Table I). 
 
Genetically modified mice reveal important players in erythropoiesis  
Only a limited amount of erythrocytosis-associated mutations in the HIF pathway proteins in 
humans have been described so far – and most of them only very recently. To unravel the 
effective role of the different HIF pathway proteins during erythropoiesis, various genetically 
modified mice have been developed in the past 15 years (Table 2).  
 
HIFαs, PHDs and VHL  
Although HIF1α was initially discovered as the isoform that activates EPO transcription,5 it 
was only after both systemic and cell-type specific HIF1α and HIF2α knockout mice were 
made that the distinct role of both these transcription factors in erythropoiesis became clear. 
HIF1α knockout mice (HIF1α-/-) are only viable up to E11.5 and these embryos show major 
defects of the cardiovascular system and the neural tube.79,80 However, the lack of HIF1α 
doesn’t lead to complete abolishment of erythropoiesis, but rather to multiple disturbances in 
the adaptive responses to hypoxia. Conversely, HIF2α deficient mice revealed that the 
observed pancytopenia is caused by abnormally low plasma EPO levels and impaired renal 
EPO induction.81 Ablation of this subunit after birth resulted in anemia accompanied by 
decreased circulatory EPO.82 Interestingly, even heterozygous deficient mice (HIF2α+/-) show 
a mild form of anemia (K.F. and B.W., unpublished data, October 21, 2011). The group of Dr. 
Haase was able to demonstrate that the regulation of erythropoiesis is essentially driven by 
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renal HIF2α.83 Indeed, specific deletion of HIF2α in the kidney resulted in EPO-dependent 
anemia, which was only partially compensated by hepatic HIF2α.83 Moreover, although both 
HIF isoforms are expressed in the kidney, only HIF2α is found in the peritubular interstitial 
cells,32,74 and co-localized with EPO mRNA in these cells.84 At the molecular level, it was 
shown that HIF2α is actually the major isoform binding the 3’ enhancer of the EPO gene in 
its native form, whereas HIF1α primarily binds to the isolated HRE, as initially described.4,5,85 
Moreover, the existence of additional transcription factors that bind to sites outside the actual 
HRE which promote the preferential binding of HIF2α has been proposed, too.85 Recently, the 
group of Dr. Lee presented a new mouse line bearing a G536W missense mutation in HIF2α 
that corresponds to the first such human mutation identified (G537W). Remarkably, these 
mice not only showed elevated hematocrit and pulmonary hypertension, these findings attest 
that missense mutations in HIF2α can indeed cause erythrocytosis.86  
 
The HIFα subunits are regulated by different PHDs- the oxygen sensors. However, it is only 
after the mutant mouse lines were made that the functional differences between the family 
members became clear. Indeed, systemic deletion of PHD2, leads to embryonic lethality due 
to placental and heart defects, whereas PHD1 and PHD3-specific knockout mice do not show 
any apparent abnormalities.87 Inducible PHD2-deficient mice on the other hand, develop 
severe erythrocytosis and show decreased life expectancy.88,89 Mice that are systemically 
deficient for either PHD1 or PHD3 do not display increased hematocrit values, and only mice 
lacking both these isoforms simultaneously develop a moderate form of erythrocytosis. In the 
latter mice, plasma EPO and renal EPO expression is decreased while hepatic EPO mRNA is 
induced.89 Thus, PHD1 and PHD3 appear to have only minor roles in the regulation of EPO 
expression, although their additional loss in the background of PHD2-deficiency can 
ameliorate the erythrocytosis phenotype.90,91 Our research group recently developed a 
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conditional PHD2-deficient mouse line displaying severe but non-lethal erythrocytosis.92 
Using different genetic approaches (PHD2/HIFα double deficient mice) we could show that 
the EPO-dependent red blood cell increase is driven by HIF2α, which is in line with other 
observations made in familial erythrocytosis.69,93 Conversely, we found that HIF1α actually 
serves as a protective factor in these PHD2-deficient mice via the local induction of PHD3.92  
 
Mice carrying a homozygous deletion of the VHL gene die in utero due to a defect in 
placental vasculogenesis.94 A liver specific VHL deletion led to hepatic vascular tumors and 
erythrocytosis, which was accompanied by increased EPO levels.95 The increase in 
erythrocytes was not reversible by additional hepatic HIF1α deletion,96  but only by deletion 
of HIF2α.85 Mice with an astrocyte specific deletion of VHL not only exhibit a significant 
increase in cerebral EPO mRNA but also a significant induction of plasma EPO  and 
erythrocytosis.16 The additional deletion of HIF1α did not correct this increase in red blood 
cell count but rather made the phenotype more severe and shortened the survival time of these 
double deficient mice. On the other hand, elimination of HIF2α along with VHL normalized 
the red blood cell count and most of the cerebral EPO transcript.16 Recently, ablation of VHL 
in osteoblasts led to HIF2α-dependent EPO induction in these cells, accompanied by 
erythrocytosis and enhanced bone formation.97 In 2007, a mouse line carrying the 
homozygous R200W mutation (leading to Chuvash erythrocytosis in humans) was created. 
Interestingly, this point mutation resulted in moderate erythrocytosis accompanied by splenic 
erythropoiesis.98 Embryonic stem cells carrying this mutation exhibited normoxic stabilization 
of HIF2α, which was accompanied by up-regulation of HIF2α-targets like VEGF. 
 
Conclusion 
13 
 
Deregulation of EPO transcription due to mutations in HIF pathway proteins is an important 
underlying cause of erythrocytosis in patients. Moreover, these mutations can also result in 
other pathologies like tumor development. Recently, various point-mutations in the 
HIF2α/EPAS1, VHL and PHD2 genes have been identified and additional studies have led to 
new insights into the HIF pathway. Complementary to these mutations, many genetically 
modified mice have provided a powerful tool to study the effect and location of HIF pathway 
members in relation to erythropoiesis and additional risk factors. Furthermore, it might be of 
great interest to develop new mouse models for erythrocytosis and related diseases including 
mice carrying specific point mutations found in humans (as mentioned above for the R200W 
VHL and very recently the G537W HIF2α mutation). 
Acknowledgements 
We thank the entire Wielockx lab for helpful discussions and Dr. Soulafa Mamlouk and Dr. 
Vasuprada Iyengar in particular for critical reading of the manuscript. B.W. is an Emmy 
Noether research fellow (DFG). Work in the lab of Ben Wielockx has been supported by 
grants from the MeDDrive-Programm (TU Dresden, Germany) and the DFG (WI 3291/1-1 
and 1-2). Work in the lab of Max Gassmann has been supported by the Swiss National 
Science Foundation. This review is a collaborative work within the COST Action TD0901 
“HypoxiaNet”. We apologize to our colleagues whose work was not cited due to space 
limitations. 
 
Author contribution 
K.F. and B.W. wrote the manuscript. M.G. provided helpful discussions and helped write the 
manuscript. 
 
Conflict of interest 
14 
 
The authors declare that there are no competing financial interests. 
   
15 
 
References 
 
1. Jourdanet D. Influence de la Pression de L'air sur la Vie de L'homme. Paris: Masson. 
1875. 
2. Miyake T, Kung CK, Goldwasser E. Purification of human erythropoietin. J Biol 
Chem. 1977;252(15):5558-5564. 
3. Jacobs K, Shoemaker C, Rudersdorf R, et al. Isolation and characterization of genomic 
and cDNA clones of human erythropoietin. Nature. 1985;313(6005):806-810. 
4. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein 
synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional 
activation. Mol Cell Biol. 1992;12(12):5447-5454. 
5. Wang GL, Jiang BH, Rue EA, Semenza GL. Hypoxia-inducible factor 1 is a basic-
helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci U S A. 
1995;92(12):5510-5514. 
6. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in 
transcriptional response to hypoxia. Proc Natl Acad Sci U S A. 1993;90(9):4304-4308. 
7. Firth JD, Ebert BL, Pugh CW, Ratcliffe PJ. Oxygen-regulated control elements in the 
phosphoglycerate kinase 1 and lactate dehydrogenase A genes: similarities with the 
erythropoietin 3' enhancer. Proc Natl Acad Sci U S A. 1994;91(14):6496-6500. 
8. Nagao M, Ebert BL, Ratcliffe PJ, Pugh CW. Drosophila melanogaster SL2 cells 
contain a hypoxically inducible DNA binding complex which recognises mammalian HIF-
binding sites. FEBS Lett. 1996;387(2-3):161-166. 
9. Jacobson LO, Goldwasser E, Fried W, Plzak L. Role of the kidney in erythropoiesis. 
Nature. 1957;179(4560):633-634. 
10. Koury ST, Bondurant MC, Koury MJ. Localization of erythropoietin synthesizing 
cells in murine kidneys by in situ hybridization. Blood. 1988;71(2):524-527. 
11. Koury ST, Koury MJ, Bondurant MC, Caro J, Graber SE. Quantitation of 
erythropoietin-producing cells in kidneys of mice by in situ hybridization: correlation with 
hematocrit, renal erythropoietin mRNA, and serum erythropoietin concentration. Blood. 
1989;74(2):645-651. 
12. Bachmann S, Hir ML, Eckardt KU. Co-localization of erythropoietin mRNA and ecto-
5'-nucleotidase immunoreactivity in peritubular cells of rat renal cortex indicates that 
fibroblasts produce erythropoietin. J Histochem Cytochem. 1993;41(3):335-341. 
13. Maxwell PH, Osmond MK, Pugh CW, et al. Identification of the renal erythropoietin-
producing cells using transgenic mice. Kidney Int. 1993;44(5):1149-1162. 
14. Obara N, Suzuki N, Kim K, Nagasawa T, Imagawa S, Yamamoto M. Repression via 
the GATA box is essential for tissue-specific erythropoietin gene expression. Blood. 
2008;111(10):5223-5232. 
15. Marti HH, Wenger RH, Rivas LA, et al. Erythropoietin gene expression in human, 
monkey and murine brain. Eur J Neurosci. 1996;8(4):666-676. 
16. Weidemann A, Kerdiles YM, Knaup KX, et al. The glial cell response is an essential 
component of hypoxia-induced erythropoiesis in mice. J Clin Invest. 2009;119(11):3373-
3383. 
17. Sakanaka M, Wen TC, Matsuda S, et al. In vivo evidence that erythropoietin protects 
neurons from ischemic damage. Proc Natl Acad Sci U S A. 1998;95(8):4635-4640. 
18. Soliz J, Joseph V, Soulage C, et al. Erythropoietin regulates hypoxic ventilation in 
mice by interacting with brainstem and carotid bodies. J Physiol. 2005;568(Pt 2):559-571. 
16 
 
19. Miskowiak K, Inkster B, Selvaraj S, Wise R, Goodwin GM, Harmer CJ. 
Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 
3 days post administration. Neuropsychopharmacology. 2008;33(3):611-618. 
20. Richmond TD, Chohan M, Barber DL. Turning cells red: signal transduction mediated 
by erythropoietin. Trends Cell Biol. 2005;15(3):146-155. 
21. Hattangadi SM, Wong P, Zhang L, Flygare J, Lodish HF. From stem cell to red cell: 
regulation of erythropoiesis at multiple levels by multiple proteins, RNAs, and chromatin 
modifications. Blood. 2011;118(24):6258-6268. 
22. Bauer A, Tronche F, Wessely O, et al. The glucocorticoid receptor is required for 
stress erythropoiesis. Genes Dev. 1999;13(22):2996-3002. 
23. Broudy VC, Lin NL, Priestley GV, Nocka K, Wolf NS. Interaction of stem cell factor 
and its receptor c-kit mediates lodgment and acute expansion of hematopoietic cells in the 
murine spleen. Blood. 1996;88(1):75-81. 
24. Lenox LE, Perry JM, Paulson RF. BMP4 and Madh5 regulate the erythroid response 
to acute anemia. Blood. 2005;105(7):2741-2748. 
25. Ramos P, Casu C, Gardenghi S, et al. Macrophages support pathological 
erythropoiesis in polycythemia vera and beta-thalassemia. Nat Med. 2013. 
26. Jewell UR, Kvietikova I, Scheid A, Bauer C, Wenger RH, Gassmann M. Induction of 
HIF-1alpha in response to hypoxia is instantaneous. FASEB J. 2001;15(7):1312-1314. 
27. Fandrey J, Gorr TA, Gassmann M. Regulating cellular oxygen sensing by 
hydroxylation. Cardiovasc Res. 2006;71(4):642-651. 
28. Xia X, Lemieux ME, Li W, et al. Integrative analysis of HIF binding and 
transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl 
Acad Sci U S A. 2009;106(11):4260-4265. 
29. Schodel J, Oikonomopoulos S, Ragoussis J, Pugh CW, Ratcliffe PJ, Mole DR. High-
resolution genome-wide mapping of HIF-binding sites by ChIP-seq. Blood. 
2011;117(23):e207-217. 
30. Ivan M, Kondo K, Yang H, et al. HIFalpha targeted for VHL-mediated destruction by 
proline hydroxylation: implications for O2 sensing. Science. 2001;292(5516):464-468. 
31. Jaakkola P, Mole DR, Tian YM, et al. Targeting of HIF-alpha to the von Hippel-
Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 
2001;292(5516):468-472. 
32. Epstein AC, Gleadle JM, McNeill LA, et al. C. elegans EGL-9 and mammalian 
homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell. 
2001;107(1):43-54. 
33. Berra E, Benizri E, Ginouvès A, Volmat V, Roux D, Pouysségur J. HIF prolyl-
hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in 
normoxia. EMBO J. 2003;22(16):4082-4090. 
34. Oehme F, Ellinghaus P, Kolkhof P, et al. Overexpression of PH-4, a novel putative 
proline 4-hydroxylase, modulates activity of hypoxia-inducible transcription factors. Biochem 
Biophys Res Commun. 2002;296(2):343-349. 
35. Wiesener MS, Jürgensen JS, Rosenberger C, et al. Widespread hypoxia-inducible 
expression of HIF-2alpha in distinct cell populations of different organs. FASEB J. 
2003;17(2):271-273. 
36. Hu C-J, Wang L-Y, Chodosh LA, Keith B, Simon MC. Differential roles of hypoxia-
inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell 
Biol. 2003;23(24):9361-9374. 
37. van Patot MC, Gassmann M. Hypoxia: adapting to high altitude by mutating EPAS-1, 
the gene encoding HIF-2alpha. High Alt Med Biol. 2011;12(2):157-167. 
17 
 
38. Branco-Price C, Zhang N, Schnelle M, et al. Endothelial cell HIF-1alpha and HIF-
2alpha differentially regulate metastatic success. Cancer Cell. 2012;21(1):52-65. 
39. Raval RR, Lau KW, Tran MGB, et al. Contrasting properties of hypoxia-inducible 
factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol Cell 
Biol. 2005;25(13):5675-5686. 
40. Petrella BL, Lohi J, Brinckerhoff CE. Identification of membrane type-1 matrix 
metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal 
cell carcinoma. Oncogene. 2005;24(6):1043-1052. 
41. Covello KL, Kehler J, Yu H, et al. HIF-2alpha regulates Oct-4: effects of hypoxia on 
stem cell function, embryonic development, and tumor growth. Genes Dev. 2006;20(5):557-
570. 
42. Chen F, Zhang W, Liang Y, et al. Transcriptome and network changes in climbers at 
extreme altitudes. PLoS One. 2012;7(2):e31645. 
43. Sergeyeva A, Gordeuk VR, Tokarev YN, Sokol L, Prchal JF, Prchal JT. Congenital 
polycythemia in Chuvashia. Blood. 1997;89(6):2148-2154. 
44. Ang SO, Chen H, Gordeuk VR, et al. Endemic polycythemia in Russia: mutation in 
the VHL gene. Blood Cells Mol Dis. 2002;28(1):57-62. 
45. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies 
congenital Chuvash polycythemia. Nat Genet. 2002;32(4):614-621. 
46. Russell RC, Sufan RI, Zhou B, et al. Loss of JAK2 regulation via a heterodimeric 
VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia. Nat Med. 2011;17(7):845-
853. 
47. Bushuev VI, Miasnikova GY, Sergueeva AI, et al. Endothelin-1, vascular endothelial 
growth factor and systolic pulmonary artery pressure in patients with Chuvash polycythemia. 
Haematologica. 2006;91(6):744-749. 
48. Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital disorder of oxygen 
sensing: association of the homozygous Chuvash polycythemia VHL mutation with 
thrombosis and vascular abnormalities but not tumors. Blood. 2004;103(10):3924-3932. 
49. Sable CA, Aliyu ZY, Dham N, et al. Pulmonary artery pressure and iron deficiency in 
patients with upregulation of hypoxia sensing due to homozygous VHL(R200W) mutation 
(Chuvash polycythemia). Haematologica. 2012;97(2):193-200. 
50. Gordeuk VR, Prchal JT. Vascular complications in Chuvash polycythemia. Semin 
Thromb Hemost. 2006;32(3):289-294. 
51. Liu X, Hao L, Zhang S, et al. Genetic repression of mouse VEGF expression regulates 
coagulation cascade. IUBMB Life. 2010;62(11):819-824. 
52. Sergueeva AI, Miasnikova GY, Okhotin DJ, et al. Elevated homocysteine, glutathione 
and cysteinylglycine concentrations in patients homozygous for the Chuvash polycythemia 
VHL mutation. Haematologica. 2008;93(2):279-282. 
53. Perrotta S, Nobili B, Ferraro M, et al. Von Hippel-Lindau-dependent polycythemia is 
endemic on the island of Ischia: identification of a novel cluster. Blood. 2006;107(2):514-519. 
54. Liu E, Percy MJ, Amos CI, et al. The worldwide distribution of the VHL 598C>T 
mutation indicates a single founding event. Blood. 2004;103(5):1937-1940. 
55. Lee FS, Percy MJ. The HIF pathway and erythrocytosis. Annu Rev Pathol. 
2011;6:165-192. 
56. Bond J, Gale DP, Connor T, et al. Dysregulation of the HIF pathway due to VHL 
mutation causing severe erythrocytosis and pulmonary arterial hypertension. Blood. 
2011;117(13):3699-3701. 
57. Lanikova L, Lorenzo F, Yang C, et al. Novel homozygous VHL mutation in exon 2 is 
associated with congenital polycythemia but not with cancer. Blood. 2013. 
18 
 
58. Tomasic NL, Piterkova L, Huff C, et al. The phenotype of polycythemia due to 
Croatian homozygous VHL (571C>G:H191D) mutation is different from that of Chuvash 
polycythemia (VHL 598C>T:R200W). Haematologica. 2013;98(4):560-567. 
59. Pastore Y, Jedlickova K, Guan Y, et al. Mutations of von Hippel-Lindau tumor-
suppressor gene and congenital polycythemia. Am J Hum Genet. 2003;73(2):412-419. 
60. Nordstrom-O'Brien M, van der Luijt RB, van Rooijen E, et al. Genetic analysis of von 
Hippel-Lindau disease. Hum Mutat. 2010;31(5):521-537. 
61. Albiero E, Ruggeri M, Fortuna S, et al. Analysis of the oxygen sensing pathway genes 
in familial chronic myeloproliferative neoplasms and identification of a novel EGLN1 germ-
line mutation. Br J Haematol. 2011;153(3):405-408. 
62. Albiero E, Ruggeri M, Fortuna S, et al. Isolated erythrocytosis: study of 67 patients 
and identification of three novel germ-line mutations in the prolyl hydroxylase domain protein 
2 (PHD2) gene. Haematologica. 2012;97(1):123-127. 
63. Ladroue C, Hoogewijs D, Gad S, et al. Distinct deregulation of the hypoxia inducible 
factor by PHD2 mutants identified in germline DNA of patients with polycythemia. 
Haematologica. 2012;97(1):9-14. 
64. Percy MJ, Zhao Q, Flores A, et al. A family with erythrocytosis establishes a role for 
prolyl hydroxylase domain protein 2 in oxygen homeostasis. Proc Natl Acad Sci U S A. 
2006;103(3):654-659. 
65. Pappalardi MB, Martin JD, Jiang Y, et al. Biochemical characterization of human 
prolyl hydroxylase domain protein 2 variants associated with erythrocytosis. Biochemistry. 
2008;47(43):11165-11167. 
66. Percy MJ, Furlow PW, Beer PA, Lappin TRJ, McMullin MF, Lee FS. A novel 
erythrocytosis-associated PHD2 mutation suggests the location of a HIF binding groove. 
Blood. 2007;110(6):2193-2196. 
67. Al-Sheikh M, Moradkhani K, Lopez M, Wajcman H, Préhu C. Disturbance in the HIF-
1alpha pathway associated with erythrocytosis: further evidences brought by frameshift and 
nonsense mutations in the prolyl hydroxylase domain protein 2 (PHD2) gene. Blood Cells 
Mol Dis. 2008;40(2):160-165. 
68. Ladroue C, Carcenac R, Leporrier M, et al. PHD2 mutation and congenital 
erythrocytosis with paraganglioma. N Engl J Med. 2008;359(25):2685-2692. 
69. Percy MJ, Furlow PW, Lucas GS, et al. A gain-of-function mutation in the HIF2A 
gene in familial erythrocytosis. N Engl J Med. 2008;358(2):162-168. 
70. Percy MJ, Chung YJ, Harrison C, et al. Two new mutations in the HIF2A gene 
associated with erythrocytosis. Am J Hematol. 2012. 
71. Beall CM, Cavalleri GL, Deng L, et al. Natural selection on EPAS1 (HIF2alpha) 
associated with low hemoglobin concentration in Tibetan highlanders. Proc Natl Acad Sci U S 
A. 2010;107(25):11459-11464. 
72. Simonson TS, Yang Y, Huff CD, et al. Genetic evidence for high-altitude adaptation 
in Tibet. Science. 2010;329(5987):72-75. 
73. Lorenzo FR, Yang C, Ng Tang Fui M, et al. A novel EPAS1/HIF2A germline 
mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl). 
2013;91(4):507-512. 
74. Zhuang Z, Yang C, Lorenzo F, et al. Somatic HIF2A gain-of-function mutations in 
paraganglioma with polycythemia. N Engl J Med. 2012;367(10):922-930. 
75. Yang C, Sun MG, Matro J, et al. Novel HIF2A mutations disrupt oxygen sensing, 
leading to polycythemia, paragangliomas, and somatostatinomas. Blood. 2013;121(13):2563-
2566. 
19 
 
76. Comino-Mendez I, de Cubas AA, Bernal C, et al. Tumoral EPAS1 (HIF2A) mutations 
explain sporadic pheochromocytoma and paraganglioma in the absence of erythrocytosis. 
Hum Mol Genet. 2013. 
77. Taieb D, Yang C, Delenne B, et al. First Report of Bilateral Pheochromocytoma in the 
Clinical Spectrum of HIF2A-Related Polycythemia-Paraganglioma Syndrome. J Clin 
Endocrinol Metab. 2013. 
78. Toledo RA, Qin Y, Srikantan S, et al. In vivo and in vitro oncogenic effects of HIF2A 
mutations in pheochromocytomas and paragangliomas. Endocr Relat Cancer. 2013. 
79. Iyer NV, Kotch LE, Agani F, et al. Cellular and developmental control of O2 
homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev. 1998;12(2):149-162. 
80. Ryan HE, Lo J, Johnson RS. HIF-1 alpha is required for solid tumor formation and 
embryonic vascularization. EMBO J. 1998;17(11):3005-3015. 
81. Scortegagna M, Ding K, Zhang Q, et al. HIF-2alpha regulates murine hematopoietic 
development in an erythropoietin-dependent manner. Blood. 2005;105(8):3133-3140. 
82. Gruber M, Hu C-J, Johnson RS, Brown EJ, Keith B, Simon MC. Acute postnatal 
ablation of Hif-2alpha results in anemia. Proc Natl Acad Sci U S A. 2007;104(7):2301-2306. 
83. Kapitsinou PP, Liu Q, Unger TL, et al. Hepatic HIF-2 regulates erythropoietic 
responses to hypoxia in renal anemia. Blood. 2010;116(16):3039-3048. 
84. Paliege A, Rosenberger C, Bondke A, et al. Hypoxia-inducible factor-2alpha-
expressing interstitial fibroblasts are the only renal cells that express erythropoietin under 
hypoxia-inducible factor stabilization. Kidney Int. 2010;77(4):312-318. 
85. Rankin EB, Biju MP, Liu Q, et al. Hypoxia-inducible factor-2 (HIF-2) regulates 
hepatic erythropoietin in vivo. J Clin Invest. 2007;117(4):1068-1077. 
86. Tan Q, Kerestes H, Percy MJ, et al. Erythrocytosis and Pulmonary Hypertension in a 
Mouse Model of Human HIF2A Gain-of-Function Mutation. J Biol Chem. 2013. 
87. Takeda K, Ho VC, Takeda H, Duan L-J, Nagy A, Fong G-H. Placental but not heart 
defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking 
prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006;26(22):8336-8346. 
88. Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin WG. 
Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive 
heart failure. Blood. 2008;111(6):3236-3244. 
89. Takeda K, Aguila HL, Parikh NS, et al. Regulation of adult erythropoiesis by prolyl 
hydroxylase domain proteins. Blood. 2008;111(6):3229-3235. 
90. Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin WG. A 
feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response 
in vivo. Mol Cell Biol. 2009;29(21):5729-5741. 
91. Minamishima YA, Kaelin WG. Reactivation of hepatic EPO synthesis in mice after 
PHD loss. Science. 2010;329(5990):407. 
92. Franke K, Kalucka J, Mamlouk S, et al. HIF-1alpha is a protective factor in 
conditional PHD2-deficient mice suffering from severe HIF-2alpha-induced excessive 
erythropoiesis. Blood. 2013;121(8):1436-1445. 
93. Percy MJ, Beer PA, Campbell G, et al. Novel exon 12 mutations in the HIF2A gene 
associated with erythrocytosis. Blood. 2008;111(11):5400-5402. 
94. Gnarra JR, Ward JM, Porter FD, et al. Defective placental vasculogenesis causes 
embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A. 1997;94(17):9102-
9107. 
95. Haase VH, Glickman JN, Socolovsky M, Jaenisch R. Vascular tumors in livers with 
targeted inactivation of the von Hippel-Lindau tumor suppressor. Proc Natl Acad Sci U S A. 
2001;98(4):1583-1588. 
20 
 
96. Rankin EB, Higgins DF, Walisser JA, Johnson RS, Bradfield CA, Haase VH. 
Inactivation of the arylhydrocarbon receptor nuclear translocator (Arnt) suppresses von 
Hippel-Lindau disease-associated vascular tumors in mice. Mol Cell Biol. 2005;25(8):3163-
3172. 
97. Rankin EB, Wu C, Khatri R, et al. The HIF Signaling Pathway in Osteoblasts Directly 
Modulates Erythropoiesis through the Production of EPO. Cell. 2012;149(1):63-74. 
98. Hickey MM, Lam JC, Bezman NA, Rathmell WK, Simon MC. von Hippel-Lindau 
mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha 
signaling and splenic erythropoiesis. J Clin Invest. 2007;117(12):3879-3889. 
99. Mazzone M, Dettori D, de Oliveira RL, et al. Heterozygous deficiency of PHD2 
restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell. 
2009;136(5):839-851. 
100. Scortegagna M, Ding K, Oktay Y, et al. Multiple organ pathology, metabolic 
abnormalities and impaired homeostasis of reactive oxygen species in Epas1-/- mice. Nat 
Genet. 2003;35(4):331-340. 
 
 
 
 
  
21 
 
Figure 1: Oxygen-dependent regulation of HIFα and its target genes. If oxygen demand is 
covered, HIFα becomes constantly hydroxylated by PHDs, and subsequently undergoes 
proteasomal degradation after binding with VHL. Under hypoxic conditions, HIFα is 
stabilized, translocates to the nucleus, binds to its heterodimerization partner HIFβ as well as 
to other co-factors, and leads to the transcriptional activation of target genes that harbor HRE 
sequences in their promoter region. HIF1α and HIF2α share target genes (green) but have 
certain preferences (preferentially induced by HIF1α in yellow; by HIF2α in blue) (HIF: 
hypoxia inducible factor, PHD: prolyl hydroxylase, VHL: von Hippel-lindau, CBP: CREB-
binding protein, HRE: hypoxia responsive element). 
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Table 1: HIF pathway related mutations that have resulted in erythrocytosis and/or tumor 
development in humans.  
 
 
Gene Type of mutation mutation erythrocytosis Tumor type Ref. 
VHL Germline (Homo>>Hetero) R200W + - 45,55 
 Germline (Homo)  H191D P138L + - 57-59 
 Germline ((Compound) Hetero) 
Various 
(including 
R200W) 
+ - 55,56 
 Somatic/ Germline (Hetero) various - 
e.g. spinal 
hemangioblastoma, 
renal cell carcinoma 
(RCC) and 
pheochromocytoma 
60 
PHD2 Germline (Hetero) various + - 55,61-64,66,67 
 Germline (Hetero) H374R + paraganglioma 68 
HIF2α Germline (Hetero) 
Various 
(including 
G537W) 
+ - 55,69,70 
 Germline (Hetero) F374Y + pheochromocytoma/ paraganglioma 73 
 Somatic (Hetero) A530V A530T + 
paragangliomas/ 
somatostatinoma 74 
 Somatic (Hetero) various +/- 
Pheochromocytomas
/ paragangliomas / 
somatostatinoma 
75-78 
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Table 2: Available genetically modified mice illustrating the impact of a deregulated HIF 
system on murine erythropoiesis. 
* in anemic mice and during early postnatal development 
 
Gene Type of modification Phenotype mice Ref. 
VHL Liver specific KO erythrocytosis 95 
 Brain specific KO erythrocytosis 16 
 R200W mutation erythrocytosis 98 
PHD2 Induced complete KO erythrocytosis 88,89 
 Conditional KO (including EPO-producing cells in kidney and brain) erythrocytosis 92 
 Heterozygosity mild erythrocytosis 99 
HIF2α Complete KO pancytopenia 100 
 Induced complete KO anemia 82 
 Liver specific KO anemia * 85 * 83 
 Kidney specific KO anemia 83 
 Heterozygosity mild anemia unpublished 
 G536W mutation erythrocytosis 86 
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